Genetic Technologies Balance Sheet Health
Financial Health criteria checks 6/6
Genetic Technologies has a total shareholder equity of A$4.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$8.5M and A$3.7M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
Interest coverage ratio | n/a |
Cash | AU$3.73m |
Equity | AU$4.81m |
Total liabilities | AU$3.65m |
Total assets | AU$8.47m |
Recent financial health updates
Recent updates
Genetic acquires AffinityDNA to bolster direct-to-consumer business
Jul 14Infinity Biologix launches Genetic Technologies' COVID-19 test
Jun 09Genetic Technologies launches COVID-19 risk test through partnership with Infinity Biologix
Jun 01Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.
Apr 26Genetic Technologies appoints new CEO; Shares are up 8%
Jan 04Financial Position Analysis
Short Term Liabilities: GENE's short term assets (A$5.7M) exceed its short term liabilities (A$3.4M).
Long Term Liabilities: GENE's short term assets (A$5.7M) exceed its long term liabilities (A$232.9K).
Debt to Equity History and Analysis
Debt Level: GENE is debt free.
Reducing Debt: GENE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GENE has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: GENE is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.